Arbutus Biopharma is a publicly-traded (NASDAQ:ABUS) biopharmaceutical company dedicated to discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection, a disease of the liver caused by hepatitis B virus (HBV). We are developing a portfolio of drug candidates with multiple mechanisms of action that we believe will result in a combination therapy that will transform the HBV treatment landscape and cure hepatitis B virus disease. Source
No articles found.
Lipocine Inc. is a clinical-stage biopharmaceutical company focused on metabolic a...
Lipocine Inc. is a clinical-stage biopharmaceut...
Prothena Corporation plc (Nasdaq: PRTA) is a clinical-stage neuroscience company f...
Prothena Corporation plc (Nasdaq: PRTA) is a cl...
At MannKind Corporation (NASDAQ: MNKD), we focus on the discovery, development and...
At MannKind Corporation (NASDAQ: MNKD), we focu...
YiLo Life uses organic methods and the finest ingredients to create cannabis produ...
YiLo Life uses organic methods and the finest i...
Agios is a biopharmaceutical company passionately committed to applying our scient...
Agios is a biopharmaceutical company passionate...
We are a biopharmaceutical company dedicated to the development of programmed cell...
We are a biopharmaceutical company dedicated to...
Assembly Biosciences is advancing a new class of oral therapeutics for the treatme...
Assembly Biosciences is advancing a new class o...
Join the National Investor Network and get the latest information with your interests in mind.